Brands, dedicated private labelers, and co-manufacturers can take advantage of the private labeling opportunity, and would benefit from developing a wide range of products to fit every category and access to R&D to meet unique needs of customers.
Plants can serve as expression platforms similar to microorganisms used as recombinant protein hosts. This may require minimal processing into value-added ingredients, such as egg and dairy functional proteins. Plants offer scalability with less need for expensive downstream purification to isolate proteins of interest from inedible or undesirable hosts.
Opportunity exists for a broker, marketplace, directory, or other exchange platform to facilitate B2B sales of plant-based foods as ingredients to manufacturers of frozen and prepared foods.
There has been little in the way of publicly-announced R&D or commercial efforts to develop the next generation of tasty and affordable plant-based turkey products. There is room for innovation toward different formats and more complex products with higher fidelity to conventional turkey.
Plant-based meat snacks could tap into underlying trends in snacks replacing meals and increased consumer interest in high-protein, low-sugar foods. Product innovation is needed to match the taste, price, and availability of animal options.
Opportunities exist to coordinate product development partnerships between ingredient suppliers, strategic partners, and product manufacturers to directly engage more holistically on product formulation.
Coordinated efforts to develop standardized, comprehensive research toolkits of meat-relevant species would exponentially accelerate cultivated meat research.
Open-access blueprints would provide a head start on facility design and allow equipment manufacturers and engineering companies to address standard industry needs.
Metabolic and physiological characteristics of microbial strains define the commercial potential of any fermentative process, but only a minimal number of strains have been scaled up for commercial production of alternative protein. To broaden the spectrum of available microorganisms, systematic investigation into the physiology of novel microbial strains is needed to identify strains suitable for fermentation.
Companies entering the alt protein space often struggle to secure line time at demonstration-scale and mid-scale commercial production facilities. Greater availability of mid-scale contract capacity would reduce capital outlays and facilitate scaling, allowing alt protein companies to maintain greater control over their equity and exercise more influence within the supply chain. Contracting production allows for a more modular supply chain, with participants achieving gains from specialization, allowing for better financial and organizational structuring around core competencies.
